Model Medicines discloses $5.12 million equity financing
The AI drug developer reported 37 investors against an $8 million offering target.
Model Medicines reported $5,115,268 in equity securities sold to 37 investors in a Form D filed on October 21, 2026. The first sale took place on October 15.
A further $2,884,732 remained against the $8 million offering target. The notice does not name the subscribers or identify a venture round stage.
The San Diego biotechnology company uses AI for target discovery, molecular design and preclinical drug development. Its research includes antiviral compounds and therapies targeting the BRD4 transcriptional regulator.